27.2.20263D modelling reveals how small missense mutations in the SynGAP1 protein can cause a rare childhood neurological disorder
23.6.2025Microbial Exposure Is Effective Against Immune-Mediated Diseases
13.5.2025ELIXIR Core Data Resources: Critical Databases and Services for Bioscience
27.3.2025The databases of the ELIXIR infrastructure provide information on the properties of pharmaceutical compounds
6.2.2025Patients could benefit from adjusting their medication based on genetic information
29.1.2025ELIXIR Finland: 10 years of connecting Finnish life sciences to Europe
27.12.2024600,000 whole slide images for analysis by the LUMI supercomputer: one of the largest data transfers ever made to the machine.
15.11.2024How the mother’s microbiota affects the foetal development and immune system?
22.10.2024Efficient sequencing methods are vital for studying impacts of microbes.
1.10.2024RNA interference: molecular dynamics simulations provide new information for drug design.
2.9.2024The world’s most extensive drug screening with CSC’s resources: New machine learning method speeds up screening hundred-fold.
25.7.2024CSC participated in sequencing the genome of coffee
22.7.2024CSC’s sensitive data services: valuable new insights into how big data could be used in public health in the future.
30.5.2024One of the world’s largest studies on secondary use of data
10.5.2024Finnish Use Cases 2 - report published
5.5.2024CSC has a big role for developing an infrastructure for genomic data
2.4.2024COVID-19 data was analysed on the CSC’s LUMI supercomputer
12.3.2024Against papillomavirus with CSC’s resources
5.3.2024One of the most comprehensive human genome simulations in the world
1.3.2024Launch of EOSC-ENTRUST - driving European interoperability for sensitive data access and analysis
20.2.2024Transfer of biological image data to CSC’s environment through container wrapper
1.2.2024Launch of ELIXIR-STEERS - enhancing research software management in life science
23.1.2024The degree of fragmentation of the cancer cell DNA to determine prognosis for cancer treatment
19.12.2023Secondary use of the health data
29.11.2023Studying microbiota at protein level requires CSC’s computing capacity
15.11.2023Bioremediation: purifying mining wastewater with plant-associated microbes
1.10.2023Artificial intelligence finds suitable drugs with CSC’s high-performance computing clusters
1.9.2023Translational medicine for personalised treatment
15.8.2023New drug candidates discovered for leukaemia through data analysis
10.6.2023Predicting the risk for type 1 diabetes
16.5.2023Single-cell RNA sequencing will produce a vast amount of information on diseases.
12.4.2023New information on celiac disease with Sensitive Data (SD) services by CSC
20.3.2023The microbiome of the Baltic Sea
13.2.2023Susanna Repo has joined the ELIXIR Finland team!
27.2.2023Finding cancer genes with organoids
3.1.2023A clear and standardized way to share patient data responsibly
19.12.2022Sensitive Data (SD) services for Research: SD Connect and SD Desktop
30.11.2022By sequencing it was discovered several previously unknown microbiota and genomes
20.10.2022RDMkit for agile data management
29.9.2022Statistical framework for describing the assembly of microbial communities
1.9.2022Antibiotic-resistant bacteria carry resistance genes and often become dominant in microbial populations
23.8.2022Modelling cells and simulating how they work gives a boost to personalised treatment plans
30.6.2022Allas is CSC’s data management system that research groups can also use to share data.
23.5.2022Genetic data combined with registry data makes it possible to develop measures to prevent diseases and to create more effective treatments.
8.4.2022When genetic data is combined with clinical data, one can predict individual´s disease susceptibility.
6.4.2022Finnish research team looks for risk factors of diseases associated with diabetes
15.2.2022Solutions for the secure use of data
10.2.2022CSC builds a database of pathological data
30.12.2021CSC is building an infrastructure for sensitive data
27.11.2021Algorithm may diagnose glaucoma
9.12.2021Better artificial intelligence models to support care decisions
4.10.2021Identifying cancer from blood sample DNA using algorithms
20.9.2021Surfing towards open data integration - more information in the webinar 22 September 2021!
1.12.2020Supercomputers speed up the diagnosis of diseases
11.9.2020The artificial intelligence model can identify cancer from digitalised samples
22.6.2020Digitalisation is revolutionising pathology
4.6.2020ELIXIR launches new EU Project — B1MG
22.5.2020The artificial intelligence model searches breast cancer interacting gene variants
14.4.2020Metabolic changes caused by illness, diet or medication can be monitored and understood
23.3.2020Deep learning algorithms for breast cancer risk analysis
24.2.2020Artificial intelligence helps assess the risk factors for breast cancer
14.2.2020A trained dog can identify a smell of cancer
23.1.2020Looking for a Programme Coordinator - ELIXIR Finland
15.1.2020Approval of three new GA4GH standards supporting automation of the data access process
12.12.2019A Versatile Computing Platform for Life and Health Sciences
25.11.2019Bioinformatics calls for a lot of constantly updated courses and analysis software to support the work of researchers
13.11.2019SisuID authentication solution
8.10.2019Objective is to create an assessment, based on health data, of each person’s risk of cardiovascular diseases
10.9.2019To develop targeted treatments for venous diseases
6.9.2019Interested in a research visit to Europe or inviting a researcher to your group?
22.8.2019Access to numerous bioinformatics services through secure user ID management
5.7.2019A unique genetic background has enabled the study of rare diseases
16.6.2019VEIL.AI anonymises patient data better and faster than traditional methods
23.5.2019Electron microscope imaging of tissues and cells helps to understand interaction between cells
25.4.2019Mice are of great assistance in the study of human diseases
7.3.2019New infrastructure to facilitate bioimaging
1.3.2019New imaging techniques can be used to diagnose diseases
21.1.2019There is still work to do to achieve uniform data processing, analysis and principles of use
12.12.2018Clinical and research data collected on people help resolving the underlying genes behind various diseases
13.11.2018The underlying mechanisms of cardiovascular diseases are studied through genetic variation
12.11.2018Laura Elo and her research group develop methods to find different predictive markers for diseases
25.10.2018Finnish User Cases
1.10.2018Genomic data management services available as part of the ELIXIR infrastructure
12.9.2018The eSISu project securely stores the details in Finnish genomes to improve investigating hereditary diseases
15.5.2018With vaccine against diarrhoea
7.5.2018Finnish biobank operators discuss IT matters
24.4.2018Suitable drug and correct dosage with an interpretation algorithm
19.3.2018Bank of million patient samples getting bigger
20.2.2018Mapping the genomes of all organisms enables the development of new vaccines and medicines
7.2.2018REMS-software: ordered and secured
11.8.2017Better harvests via bio technology
2.11.2017Utilising genomic data in health care
Sometimes, a change in just a single nucleotide in the genome can lead to significant health problems and the onset of disease. When such a change replaces one amino acid with another in a protein encoded by an important gene, it is referred to as a missense mutation. Such a change may seem insignificantly small at first sight, but the actual effects can be very large.
One gene that is particularly sensitive to such changes is SYNGAP1, which encodes SynGAP1 protein that is abundant in neurons of the forebrain. Reduced expression from even a single allele of this gene is enough to cause a severe neurological disorder.
The clinical picture is diverse: common symptoms include varying degrees of intellectual disability, epilepsy and features of the autism spectrum.
A single amino acid substitution in a long amino acid chain does not always result in major functional changes. In one position, the change may be harmless, but in another it may be devastating to the protein’s vital function.
For this reason, accurately assessing the impact of missense mutations requires computational methods capable of evaluating how such changes affect the protein’s structure in particular.
Pekka Postila and his research group have received a total of 230,000 dollars in funding from the California-based Cure SYNGAP1 Foundation to investigate SynGAP1 missense mutations. The aim of the research is to improve the diagnostics of SYNGAP1 missense variants by leveraging advanced computational structural analysis.
In computer simulations, the atoms of amino acids are represented as spheres, and the bonds between them behave like small springs. This allows the protein model to move and “live” much like it does inside actual cells. Using these calculations, it is possible to identify which missense mutations are likely to alter the protein’s structure in a critical way and thereby cause the neurological disorder.
Read more: